Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2014

Collaboration Agreement [Abstract]

Schedule of Related Party Transactions [Table Text Block]

The collaboration revenue the Company earned from Sanofi is detailed below:

	Year Ended December 31,
Sanofi Collaboration Revenue	2014			2013			2012
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(4,715	)	$	(30,810	)	$	(25,634	)
Substantive milestone	—			—			50,000
Reimbursement of Regeneron research and development expenses	4,806			5,639			10,702
Other	5,102			9,682			13,268
Total ZALTRAP	5,193			(15,489		)	48,336
Antibody:
Reimbursement of Regeneron research and development expenses	547,761			453,489			365,245
Reimbursement of Regeneron commercialization-related expenses	19,480			1,868			—
Regeneron's share of losses in connection with commercialization of antibodies	(41,378		)	—			—
Up-front payments to Sanofi for acquisition of rights related to two antibodies	—			(20,000		)	—
Other	10,243			10,243			10,233
Total Antibody	536,106			445,600			375,478
	$	541,299		$	430,111		$	423,814

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Year Ended December 31,
Bayer HealthCare Collaboration Revenue	2014		2013		2012
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	301,302	$	101,494	—
Sales and substantive development milestones	105,000		70,000		$	25,000
Cost-sharing of Regeneron EYLEA development expenses	23,383		20,905		34,892
Other	52,390		27,890		10,207
Total EYLEA	482,075		220,289		70,099
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	2,848		—		—
Other	10,632		—		—
Total PDGFR-beta	13,480		—		—
	$	495,555	$	220,289	$	70,099